S. Antonia

653 total citations
22 papers, 426 citations indexed

About

S. Antonia is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, S. Antonia has authored 22 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in S. Antonia's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (5 papers). S. Antonia is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (5 papers). S. Antonia collaborates with scholars based in United States, Spain and France. S. Antonia's co-authors include Eric B. Haura, Jhanelle E. Gray, Lieping Chen, Matthew B. Schabath, William J. Fulp, Anders Berglund, Ben Creelan, Steven A. Eschrich, Jamie K. Teer and Min Xie and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

S. Antonia

20 papers receiving 424 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Antonia United States	8	233	223	196	115	52	22	426
Jinyan Yang China	8	133 0.6×	124 0.6×	151 0.8×	109 0.9×	129 2.5×	11	341
Jianchang Fu China	9	126 0.5×	113 0.5×	143 0.7×	131 1.1×	106 2.0×	12	325
Jiaqi Su China	9	135 0.6×	124 0.6×	194 1.0×	113 1.0×	90 1.7×	29	353
Brienne E. Engel United States	6	207 0.9×	158 0.7×	223 1.1×	137 1.2×	29 0.6×	9	388
Maria Saigí Spain	10	142 0.6×	172 0.8×	203 1.0×	104 0.9×	66 1.3×	24	380
Dorothee Franziska Strohmer China	5	100 0.4×	98 0.4×	174 0.9×	110 1.0×	106 2.0×	6	309
Xiuju Du China	4	158 0.7×	159 0.7×	128 0.7×	124 1.1×	46 0.9×	4	307
Travis Y. Tu United States	7	71 0.3×	313 1.4×	99 0.5×	73 0.6×	251 4.8×	8	449
Ling Dai China	9	136 0.6×	238 1.1×	105 0.5×	68 0.6×	53 1.0×	28	347

Countries citing papers authored by S. Antonia

Since Specialization

Citations

This map shows the geographic impact of S. Antonia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Antonia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Antonia more than expected).

Fields of papers citing papers by S. Antonia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Antonia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Antonia. The network helps show where S. Antonia may publish in the future.

Co-authorship network of co-authors of S. Antonia

This figure shows the co-authorship network connecting the top 25 collaborators of S. Antonia. A scholar is included among the top collaborators of S. Antonia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Antonia. S. Antonia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ready, Neal, et al.. (2025). 261TiP: A single arm phase II study of PCSK9 inhibitor, alirocumab, and PD-1 inhibitor, cemiplimab, in advanced immuno-refractory metastatic non-small cell lung cancer (TOP2201). Journal of Thoracic Oncology. 20(3). S162–S162.

Senan, Suresh, Mustafa Özgüroğlu, Davey B. Daniel, et al.. (2022). Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO Open. 7(2). 100410–100410. 14 indexed citations

Spigel, David R., Delvys Rodríguez‐Abreu, Federico Cappuzzo, et al.. (2021). P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors. Journal of Thoracic Oncology. 16(3). S636–S637.

Vansteenkiste, Johan, Jarushka Naidoo, Corinne Faivre‐Finn, et al.. (2019). Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). Annals of Oncology. 30. v592–v593. 12 indexed citations

Garassino, Marina Chiara, Luis Paz‐Ares, Rina Hui, et al.. (2019). Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Annals of Oncology. 30. ii78–ii78. 1 indexed citations

Planchard, David, Marina Chiara Garassino, L. Paz-Ares, et al.. (2019). Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC). Annals of Oncology. 30. ii32–ii33. 1 indexed citations

Barlési, Fabrice, Martin Steins, Leora Horn, et al.. (2016). Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. Annals of Oncology. 27. vi420–vi420. 16 indexed citations

Sequist, Lecia V., Jennifer L. Gilbert, Paul Conkling, et al.. (2016). Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). Annals of Oncology. 27. vi493–vi493. 30 indexed citations

Schabath, Matthew B., William J. Fulp, Lieping Chen, et al.. (2015). Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 35(24). 3209–3216. 271 indexed citations

10.

Goldberg, Sarah B., Ani Sarkis Balmanoukian, Jamie E. Chaft, et al.. (2015). 3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC. European Journal of Cancer. 51. S627–S627. 3 indexed citations

11.

Chiappori, Alberto, et al.. (2014). Clinical Pathway Adherence Improvement: A Quality Engagement Initiative for Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 90(5). S62–S62. 1 indexed citations

12.

Tao, Jianguo, Lubomir Sokol, P. A. Chervenick, et al.. (2010). Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results.. Journal of Clinical Oncology. 28(15_suppl). 2608–2608. 1 indexed citations

13.

Soliman, Hatem, et al.. (2009). Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). Journal of Clinical Oncology. 27(15_suppl). 3004–3004. 31 indexed citations

14.

Chiappori, Alberto, et al.. (2008). Phase I trial evaluating the epidermal growth factor receptor inhibitor erlotinib in combination with the SRC kinase inhibitor dasatinib for patients with recurrent non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 14605–14605. 7 indexed citations

15.

Chiappori, Alberto, Marco Sereno, Dmitry I. Gabrilovich, et al.. (2007). Phase II trial of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) immunized with p53-transduced dendritic cells (p53-DC): Immune sensitization to chemotherapy (CT). Journal of Clinical Oncology. 25(18_suppl). 3012–3012. 3 indexed citations

16.

Antonia, S., Jeffrey A. Sosman, John M. Kirkwood, et al.. (2007). Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206. Journal of Clinical Oncology. 25(18_suppl). 3038–3038. 7 indexed citations

17.

Tolcher, A. W., S. Antonia, Lionel D. Lewis, et al.. (2006). A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3014–3014. 17 indexed citations

18.

Mita, Alain C., S. Antonia, Lionel D. Lewis, et al.. (2006). 29LB1 Late Breaking ORAL Final safety, pharmacokinetic and antitumor activity results of a phase I study of YM155, a novel survivin inhibitor, when administered by 168 hour continuous infusion. European Journal of Cancer Supplements. 4(12). 13–13. 1 indexed citations

19.

Bepler, Gerold, Eric Sommers, Lary A. Robinson, et al.. (2005). O-111 Neoadjuvant gemcitabine and pemetrexed (NeoGP) in resectable non-small-cell lung cancer (NSCLC). Lung Cancer. 49. S39–S39. 2 indexed citations

20.

Thompson, Patricia A., Mayer Fishman, John D. Seigne, et al.. (2005). Phase II study of B7–1 gene-modified autologous tumor cell vaccine and subcutaneous IL-2 for patients with stage IV renal cell carcinoma (RCC). Journal of Clinical Oncology. 23(16_suppl). 4502–4502. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact